<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The National Health Service <z:e sem="disease" ids="C0346627" disease_type="Neoplastic Process" abbrv="">Bowel Cancer</z:e> Screening Programme (BCSP) aims to detect earlier stage <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in asymptomatic individuals </plain></SENT>
<SENT sid="1" pm="."><plain>Early experience suggested that many participants had lower gastrointestinal symptoms before screening </plain></SENT>
<SENT sid="2" pm="."><plain>The study evaluated the prevalence of lower gastrointestinal symptoms and consultation behaviour among individuals undergoing colonoscopy at the South of Tyne BCSP Centre </plain></SENT>
<SENT sid="3" pm="."><plain>METHOD: Data were collected on <z:hpo ids='HP_0000001'>all</z:hpo> undergoing clinic assessment and colonoscopy </plain></SENT>
<SENT sid="4" pm="."><plain>Symptoms were categorized as altered bowel habit (ABH), <z:hpo ids='HP_0002573'>rectal bleeding</z:hpo> (RB), <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> (AP) and unexplained <z:hpo ids='HP_0001824'>weight loss</z:hpo> (UWL) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Symptoms were present in 65.1% (492/756) of subjects, 64.4% (431/669) of those with a non-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis and 70.1% (61/87) of those with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Among those with a non-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis, symptoms were ABH in 52% (224/431), RB in 81.4% (351/431), AP in 15.3% (66/431) and UWL in 3.0% (13/431) </plain></SENT>
<SENT sid="7" pm="."><plain>In those with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> symptoms they were ABH in 33.3% (29/87), RB in 55.2% (48/87) and AP in 11.5% (10/87) </plain></SENT>
<SENT sid="8" pm="."><plain>There was no significant difference in the prevalence of symptoms in those with a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> or non-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="9" pm="."><plain>A total of 34.2% (157/459) of individuals with symptoms had consulted their general practitioner, 28.1% (16/57) of those with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and 35.1% (141/402) without </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: A large proportion of individuals colonoscoped in the BCSP reported symptoms predating screening </plain></SENT>
<SENT sid="11" pm="."><plain>Their prevalence did not differ significantly between <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and non-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnoses </plain></SENT>
<SENT sid="12" pm="."><plain>The majority had not consulted their general practitioner </plain></SENT>
<SENT sid="13" pm="."><plain>Health promotion regarding the importance of lower gastrointestinal symptoms and a risk assessment tool to help select those needing urgent specialist assessment are required </plain></SENT>
</text></document>